News of Note—Merck Big Data; AbbVie JAK1 win; Bayer, Vanderbilt deal

Deals for European pharmas as AbbVie gets RA data win

> Merck KGaA is joining forces with non-profit Project Data Sphere as the pair eye working on a new, global cancer Big Data alliance. Release

> AbbVie has posted positive top-line results from the late-stage test of upadacitinib, its investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis. The candidate hit its primary and secondary endpoints, but two deaths hit the company's sharesJefferies however say: "The deaths were considered by investigators to have no reasonable possibility of being related to upadacitinib at the time of initial reporting.". Statement

> German pharma Bayer and the Vanderbilt University Medical Center have penned a five-year R&D alliance aimed at finding new therapies against kidney diseases. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.


Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.